Inhibition of the myostatin-signaling pathway has also been achieved by blocking the myostatin receptor activin receptor IIB (ActRIIB), improving muscle size and function in SMA mouse models [120,121]. This evidence concerns the gene MSTN and proximal spinal muscular atrophy.